News
LGND
98.35
-1.06%
-1.06
Weekly Report: what happened at LGND last week (0708-0712)?
Weekly Report · 9h ago
LIGAND PHARMACEUTICALS INC: AMENDMENT AMENDS CREDIT AGREEMENT TO INCREASE REVOLVING CREDIT FACILITY FROM $75 MLN TO $125 MLN
Reuters · 5d ago
Ligand Pharmaceuticals Price Target Raised to $140.00/Share From $135.00 by Craig-Hallum
Dow Jones · 6d ago
Ligand Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Dow Jones · 6d ago
Craig-Hallum Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $140
Benzinga · 6d ago
LIGAND PHARMACEUTICALS, INC. <LGND.O> : CRAIG-HALLUM RAISES TARGET PRICE TO $140 FROM $135
Reuters · 6d ago
Ligand Pharmaceuticals Price Target Maintained With a $144.00/Share by HC Wainwright & Co.
Dow Jones · 07/08 18:06
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $144 Price Target
Benzinga · 07/08 17:58
Buy Rating Affirmed for Ligand Pharma Following Strategic Acquisition and Enhanced Financial Projections
TipRanks · 07/08 16:35
Craig-Hallum Sticks to Their Buy Rating for Ligand Pharma (LGND)
TipRanks · 07/08 13:15
Ligand Pharmaceuticals to Buy Apeiron Biologics for $100 Million
Dow Jones · 07/08 12:12
Ligand Pharma Expands Portfolio with APEIRON Acquisition and Investment
TipRanks · 07/08 11:57
Weekly Report: what happened at LGND last week (0701-0705)?
Weekly Report · 07/08 11:57
Ligand Pharma To Acquire Apeiron Biologics For $100 Mln
NASDAQ · 07/08 11:44
Ligand to buy APEIRON Biologics for $100M, ups 2024 revenue outlook
Healthcare M&A Ligand to buy APEIRON Biologics for $100M, ups 2024 revenue outlook. The firm is also increasing its 2024 revenue guidance to be in the range of $140M to $157M. Lig and Pharmaceuticals said it will acquire APEirON for $ 100M in cash.
Seeking Alpha · 07/08 11:17
Ligand Pharma to Acquire APEIRON Biologics AG for $100M, Expects 2024 Revenue of $140M-$157M (Prior $130M-$142M) Vs $137.79M Est, 2024 Adj EPS of $5.00-$5.50 (Prior $4.25-$4.75) Vs $4.64 Est
Benzinga · 07/08 11:08
*Ligand Pharmaceuticals Raises 2024 View To Rev $140M-$157M Vs Prior Guidance $130M-$142M >LGND
Dow Jones · 07/08 11:05
*Ligand Pharmaceuticals Raises 2024 View To Adj EPS $5-Adj EPS $5.50 >LGND
Dow Jones · 07/08 11:04
*Ligand Pharmaceuticals: Transaction Will Be Immediately Accretive to EPS by Estimated $1 Per Shr on an Annualized Basis With a 50c/Shr Impact to 2024 >LGND
Dow Jones · 07/08 11:03
LIGAND PHARMACEUTICALS INC: INCREASING 2024 REVENUE GUIDANCE TO BE IN RANGE OF $140 MLN TO $157 MLN
Reuters · 07/08 11:00
More
Webull provides a variety of real-time LGND stock news. You can receive the latest news about Ligand Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.